{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:13:36Z","timestamp":1788444816414,"version":"build-2803163510"},"reference-count":17,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Clinical Medicine Development Special Fund of the Beijing Hospital Authority \u2018Sailing\u2019 Program","award":["ZLRK202532"],"award-info":[{"award-number":["ZLRK202532"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,6,16]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>HIV cure remains one of the major unsolved global health challenges. The persistence of the HIV reservoir is the key barrier to achieving viral eradication. The acute HIV infection (AHI) is crucial for reservoir establishment, making early intervention essential for long-term viral remission. Pegylated interferon-\u03b1 (Peg-IFN-\u03b1) exhibits potent antiviral and immunomodulatory properties that may enhance reservoir clearance when combined with antiretroviral therapy (ART). This study aims to evaluate the efficacy and safety of Peg-IFN-\u03b1 combined with ART in promoting reservoir reduction and immune reconstitution in individuals with AHI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This randomised, parallel-controlled, open-label clinical trial will enrol 68 participants with confirmed AHI. Eligible participants will be randomly assigned (1:1) to receive Peg-IFN-\u03b1 plus ART or ART alone. All participants will continue ART for a total of 48 weeks. The primary outcome is the percentage reduction in total HIV-1 DNA at week 48. Secondary outcomes include HIV-1 DNA reduction at week 12, CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell recovery, cytokine profiles and safety endpoints. Statistical analysis will be performed using the intention-to-treat principle. Recruitment commenced in April 2025 and is expected to complete by December 2027.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been approved by the Ethics Committee of Beijing You\u2019an Hospital, Capital Medical University (approval no. LL-2024-150-K). Written informed consent will be obtained from all participants before enrolment. The results will be disseminated through peer-reviewed publications, academic conferences and communications with the clinical and scientific community. De-identified datasets will be available to qualified researchers on reasonable request following publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2500100011.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-113287","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:40:48Z","timestamp":1782992448000},"page":"e113287","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of pegylated interferon-\u03b1 combined with antiretroviral therapy on HIV reservoir clearance in acute HIV infection: study protocol for a randomised controlled trial at a tertiary infectious disease hospital in Beijing, China"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2743-870X","authenticated-orcid":false,"given":"Luying","family":"Zhu","sequence":"first","affiliation":[{"name":"Clinical and Research Center for Infectious Diseases, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-2158","authenticated-orcid":false,"given":"Fuchun","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical and Research Center for Infectious Diseases, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8431-5465","authenticated-orcid":false,"given":"Jiahao","family":"Ji","sequence":"additional","affiliation":[{"name":"Clinical and Research Center for Infectious Diseases, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5269-3588","authenticated-orcid":false,"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Clinical and Research Center for Infectious Diseases, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4521-9228","authenticated-orcid":false,"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical and Research Center for Infectious Diseases, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[{"name":"Beijing Youan Home of Loving Care, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Liu","sequence":"additional","affiliation":[{"name":"Liver Disease Center, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1078-0306","authenticated-orcid":false,"given":"Junfeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Liver Disease Center, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingkun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"},{"name":"Center of Biobank, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"},{"name":"Center of Biobank, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-3027","authenticated-orcid":false,"given":"Lili","family":"Dai","sequence":"additional","affiliation":[{"name":"Clinical and Research Center for Infectious Diseases, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-4785","authenticated-orcid":false,"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical and Research Center for Infectious Diseases, Beijing You\u2019an Hospital Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026090306251252000_16.7.e113287.1","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010254","article-title":"Sensor Sensibility-HIV-1 and the Innate Immune Response","volume":"9","author":"Yin","year":"2020","journal-title":"Cells"},{"key":"2026090306251252000_16.7.e113287.2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav3491","article-title":"Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection","volume":"12","author":"Leyre","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026090306251252000_16.7.e113287.3","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001033"},{"key":"2026090306251252000_16.7.e113287.4","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835cae9c"},{"key":"2026090306251252000_16.7.e113287.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3449"},{"key":"2026090306251252000_16.7.e113287.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004291","article-title":"Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice","volume":"10","author":"Li","year":"2014","journal-title":"PLoS Pathog"},{"key":"2026090306251252000_16.7.e113287.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature13554"},{"key":"2026090306251252000_16.7.e113287.8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8179","article-title":"Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption","volume":"13","author":"Gondim","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026090306251252000_16.7.e113287.9","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1132699"},{"key":"2026090306251252000_16.7.e113287.10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis663"},{"key":"2026090306251252000_16.7.e113287.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.037"},{"key":"2026090306251252000_16.7.e113287.12","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0243"},{"key":"2026090306251252000_16.7.e113287.13","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/QAD.0000000000002961","article-title":"Comparable HIV suppression by pegylated-IFN-\u03b12a or pegylated-IFN-\u03b12b during a 4-week analytical treatment interruption","volume":"35","author":"Papasavvas","year":"2021","journal-title":"AIDS"},{"key":"2026090306251252000_16.7.e113287.14","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835844d9"},{"key":"2026090306251252000_16.7.e113287.15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jcv.2014.08.008","article-title":"Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial","volume":"61","author":"Cheng","year":"2014","journal-title":"J Clin Virol"},{"key":"2026090306251252000_16.7.e113287.16","first-page":"68","article-title":"Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition)","volume":"9","year":"2024","journal-title":"Chin J Infect Dis"},{"key":"2026090306251252000_16.7.e113287.17","unstructured":"National Cancer Institute (US) . Common terminology criteria for adverse events (CTCAE), version 5.0. Bethesda: National Institutes of Health, 2017."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-113287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:25:25Z","timestamp":1788441925000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-113287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2025-113287"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-113287","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}